SCHEMBL2021679

SCHEMBL2021679

NNC(=O)c1n[nH]c2ccccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.71
KDM4E B2RXH2 5/20 0.69
FLT3 P36888 2/20 0.67
CDK2 P24941 2/20 0.67
CCNA2 P20248 1/20 0.67
CCNA1 P78396 1/20 0.67
IDO1 P14902 1/20 0.63
RAB9A P51151 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
NPC1 O15118 3/20 0.62
ALDH1A1 P00352 1/20 0.62
STAT3 P40763 1/20 0.61
HIF1A Q16665 1/20 0.61
EPHB3 P54753 1/20 0.60
MAPK10 P53779 1/20 0.59
HSD17B10 Q99714 1/20 0.59
SMYD3 Q9H7B4 1/20 0.58
MEN1 O00255 1/20 0.57
GAA P10253 1/20 0.57
KMT2A Q03164 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38655498 1.00 YTHDC1 (0.71) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL20267042 0.83 SMN1; SMN2 (0.71) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL30036108 0.83 YTHDC1 (1.00) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL2723267 0.83 YTHDC1 (1.00) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL4464788 0.82 KDM4E (0.78) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL952028 0.81 SMN1; SMN2 (0.77) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL27750743 0.80 KDM4E (0.62) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL82761 0.80 KDM4E (0.62) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL12193634 0.80 KDM4E (0.53) YTHDC1KDM4EFLT3CDK2CCNA2
SCHEMBL951125 0.80 FLT3 (1.00) YTHDC1KDM4EFLT3CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479805-B2 Indazole hydrazide compound and application thereof BEIJING BAHEAL CHENGCHUANG PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. (CN) 2025-11-25 US claimed
CN-115715776-B Indazole hydrazide compound and application thereof 北京大学第一医院 2024-10-22 CN claimed
CN-118766904-A Application of indazole hydrazide compound in preparation of medicines for treating fibrosis diseases 北京大学第一医院 2024-10-15 CN claimed
CN-118026999-A Indazole hydrazide compound and application thereof in preparation of medicines for treating cancers 北京大学第一医院 2024-05-14 CN claimed
US-20230097420-A1 INDAZOLE HYDRAZIDE COMPOUND AND APPLICATION THEREOF PEKING UNIVERSITY FIRST HOSPITAL (CN) 2023-03-30 US claimed
CN-115715776-A Indazole hydrazide compound and application thereof 北京大学第一医院 2023-02-28 CN claimed
CN-112939868-B Indazole hydrazide compound and application thereof 北京大学第一医院 2022-10-18 CN claimed
WO-2022170822-A1 INDAZOLE HYDRAZIDE COMPOUND AND APPLICATION THEREOF 北京大学第一医院 2022-08-18 WO claimed
CN-113101287-A Application of indazole hydrazide compound in preparation of anti-tumor angiogenesis medicine 北京大学第一医院 2021-07-13 CN claimed
CN-112939868-A Indazole hydrazide compound and application thereof 北京大学第一医院 2021-06-11 CN claimed
CN-104356183-B Compound having anti-tumor effect as well as preparation method and application thereof 华中科技大学 2017-04-26 CN claimed
EP-1478357-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2004-11-24 EP claimed
WO-2003070236-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2003-08-28 WO claimed
CN-122036615-A Indazole hydrazide compound and preparation method and application thereof 南京农业大学 2026-05-15 CN disclosed
CN-122036615-A Indazole hydrazide compound and preparation method and application thereof 南京农业大学 2026-05-15 CN disclosed
CN-122036615-A Indazole hydrazide compound and preparation method and application thereof 南京农业大学 2026-05-15 CN disclosed
CN-101054375-A Compound capable of inhibiting tubercle bacillus growth and application thereof UNIV FUDAN (CN) 2007-10-17 CN disclosed
EP-1478357-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2004-11-24 EP disclosed
WO-2003070236-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2003-08-28 WO disclosed
US-3956312-A ANTISECRETORY AGENT EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479805-B2 Indazole hydrazide compound and application thereof ITGB3, AR, HDAC3 YTHDC1 4663/4885KDM4E 755/4885FLT3 607/4885
US-20230097420-A1 INDAZOLE HYDRAZIDE COMPOUND AND APPLICATION THEREOF ITGB3, AR, HDAC3 YTHDC1 4663/4885KDM4E 755/4885FLT3 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.